Groupe d'Etude en Oncologie du Quebec

Titre	A 6-week, randomized, double-blind, sponsor-open study to assess the effect of repeated subcutaneous administration of pf-06946860 on appetite in participants with advanced cancer and anorexia, followed by an 18-week open-label treatment period
Protocole ID	C3651010
ClinicalTrials.gov ID	NCT04803305
Type(s) de cancer	Contrôle des symptômes
Phase	Phase I
Type étude	Clinique
Médicament	PF-06946860 versus placebo
Institution	CISSS DU BAS-SAINT-LAURENT HOPITAL REGIONAL DE RIMOUSKI 150 av. Rouleau, Rimouski, QC, G5L 5T1
Ville	Rimouski
Investigateur(trice) principal(e)	Dre Marie-Claude Foley
Coordonnateur(trice)	Isabelle Gagnon 418-724-3000 poste 8029
Statut	Fermé
Critètes d'éligibilité	Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced. Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite 7-day recall scale Meets any of the following criteria at Randomization: Not currently receiving antineoplastic therapy On standard of care systemic antineoplastic therapy or treatment without curative intent Signed informed consent.
Critètes d'exclusion	Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization. Current active reversible causes of decreased food intake. Current, severe gastrointestinal disease Participants with known symptomatic brain metastases requiring steroids. Active uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, HIV or participants with known AIDS-related illness inadequate renal or liver function. Women who are pregnant or breast-feeding

Groupe d'étude en oncologie du Québec